J&J nabs new OK for IL-23 drug Tremfya; Merck KGaA spinout ups Series A tally to €20.1M
→ J&J has gotten the greenlight to add active psoriatic arthritis to Tremfya’s label. The drug “is the first and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
